Pustular psoriasis treated with IL-17a antibody secukinumab
https://doi.org/10.33667/2078-5631-2022-27-30-36
Abstract
The article presents clinical cases of treatment of acute generalized pustular psoriasis (GPP) with the use of an interleukin IL-17A inhibitor, secukinumab, which showed a remarkable response with almost complete disappearance of pustules after the first injection. To the best of our knowledge, there are limited data in the literature on evaluating the effectiveness of therapy with genetically engineered drugs in the treatment of GPP.
About the Authors
N. S. Rudneva
Tula Regional Clinical Dermatovenerologic Dispensary;
Tula State University
Russian Federation
Russian Federation
Rudneva Natalya S., PhD Med, chief physician1, associate professor at Dept
of Propaedeutics of Internal Diseases (Course of Dermatovenereology); chief
freelance specialist – dermatovenereologist, cosmetologist of the Ministry of Health of the Tula Region
Tula
E. V. Natarova
Tula Regional Clinical Dermatovenerologic Dispensary
Russian Federation
Russian Federation
Natarova Ella V., deputy chief physician for medical work
Tula
L. S. Kruglova
Central State Medical Academy of the Administrative Department of the President of Russian Federation
Russian Federation
Russian Federation
Kruglova Larisa S., DM Sci (habil.), professor, head of Dept of Dermatovenereology and Cosmetology
Moscow
References
1. Federal clinical guidelines ‘Psoriasis’ RODVK 2020. https://cr.minzdrav.gov.ru. Date of visit to the site: 27.08.21.
2. Shah M, Al Aboud DM, Crane JS, et al. Pustular Psoriasis [updated 2021 Aug 11]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK537002
3. Jeffrey J. Crowley, David M. Pariser & Paul S. Yamauchi (2021) A brief guide to pustular psoriasis for primary care providers, Postgraduate Medicine, 133: 3, 330–344, https://doi.org/10.1080/00325481.2020.1831315
4. Kubota K, Kamijima Y, Sato T, et al. Epidemiology of psoriasis and palmoplantar pustulosis: A nationwide study using the Japanese national claims database. BMJ Open. 2015; 5 (1): e006450. https://doi.org/10.1136/bmjopen-2014–006450
5. Menter A, Van Voorhees AS, Hsu S. Pustular Psoriasis: A Narrative Review of Recent Developments in Pathophysiology and Therapeutic Options. Dermatol Ther (Heidelb). 2021 Dec; 11 (6): 1917–1929. https://doi.org/10.1007/s13555–021–00612-x
6. Matushevskaia EV, Konovalova MV, Vladimirova EV, Svirshchevskaia EV. Pathogenesis and therapy of psoriasis and psoriatic arthritis. Clinical Dermatology and Venereology. 2019; 18 (5): 634–643. (In Russ.) https://doi.org/10.17116/klinderma201918051634
7. Sawabe Y, Hayashi K, Kamata M, Nagata M, Fukaya S, Fukuyasu A, Tanaka T, Ishikawa T, Ohnishi T, Komatsu H, Tanaka M, Sugiura K, Tada Y Case of generalized pustular psoriasis with coexisting mutations in IL36RN and CARD14.J Dermatol. 2019 Oct; 46 (10): e368–e370. https://doi.org/ 10.1111/1346–8138.14909
8. Gooderham MJ, Van Voorhees AS, Lebwohl MG. An update on generalized pustular psoriasis. Expert Rev Clin Immunol. 2019; 15: 907–19.
9. Ciccarelli F, De Martinis M, Sirufo MM, Ginaldi L. Psoriasis induced by anti-tumor necrosis factor alpha agents: a comprehensive review of the literature. Acta Dermatovenerol Croat. 2016; 24: 169–74. PMID: 27663916.
10. Bachelez H. Pustular psoriasis and related pustular skin diseases. Br J Dermatol. 2018; 178: 614–8.
11. Melinda J. Gooderham, Abby S. van Voorhees & Mark G. Lebwohl (2019) An update on generalized pustular psoriasis, Expert Review of Clinical Immunology, 15: 9, 907–919, https://doi.org/10.1080/1744666X.2019.1648209
12. Fujita H, Terui T, Hayama K, et al. Japanese guidelines for the management and treatment of generalized pustular psoriasis: the new pathogenesis and treatment of GPP. J Dermatol. 2018 Nov; 45 (11): 1235–1270.
13. MorphoSys. MorphoSys announces approval of Tremfya® (guselkumab) for the treatment of moderate to severe forms of psoriasis and psoriatic arthritis in Japan. 2018 Apr 6 [cited 2018 Nov 12]. Available from: https://www.morphosys.com/media-investors/media-center/morphosys-announces-approval-of-tremfyar-guselkumab-for-the-treatment
14. López-Sánchez C, Falla LM, Roé-Crespo E, Arostegui JI, Mozos A, Bernal S, Iznardo H, Baselga-Torres E Excellent response to secukinumab in an infant with severe generalized pustular psoriasis. J Dermatol. 2021 Jun; 48 (6): 907–910. https://doi.org/ 10.1111/1346–8138.15673
15. Zhou J, Luo Q, Cheng Y, Wen X, Liu J. Int An update on genetic basis of generalized pustular psoriasis (Review). J Mol Med. 2021 Jun; 47 (6): 118. https://doi.org/10.3892/ijmm.2021.4951
16. Komine M, Morita A. Generalized pustular psoriasis: current management status and unmet medical needs in Japan. Expert Rev Clin Immunol. 2021 Sep; 17 (9): 1015–1027. https://doi.org/10.1080/1744666X.2021.1961580
17. Wilsmann-Theis D, Schnell LM, Ralser-Isselstein V, Bieber T, Schön MP, Hüffmeier U, Mössner R.J Successful treatment with interleukin-17A antagonists of generalized pustular psoriasis in patients without IL36RN mutations. Dermatol. 2018 Jul; 45 (7): 850–854. https://doi.org/10.1111/1346–8138.14318
Review
For citations:
Rudneva N.S., Natarova E.V., Kruglova L.S. Pustular psoriasis treated with IL-17a antibody secukinumab. Medical alphabet. 2022;1(27):30-36. (In Russ.) https://doi.org/10.33667/2078-5631-2022-27-30-36
Views:
346
Email this article 